Wolverine Trading, LLC Editas Medicine, Inc. Transaction History

Wolverine Trading, LLC

  • $93.9 Billion
  • Q3 2024

A detailed history of Wolverine Trading, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Wolverine Trading, LLC holds 19,392 shares of EDIT stock, worth $25,403. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,392
Previous 33,500 42.11%
Holding current value
$25,403
Previous $156,000 57.69%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$3.39 - $5.96 $65,738 - $115,576
19,392 New
19,392 $66,000
Q3 2022

Nov 14, 2022
BUY
$12.16 - $19.42 $199,655 - $318,856
16,419 New
16,419 $200,000
Q1 2022

May 16, 2022
BUY
$14.08 - $27.63 $35,608 - $69,876
2,529 Added 11.35%
24,816 $484,000
Q4 2021

Feb 14, 2022
BUY
$26.55 - $40.57 $460,297 - $703,362
17,337 Added 350.24%
22,287 $619,000
Q3 2021

Nov 12, 2021
SELL
$39.27 - $72.94 $895,238 - $1.66 Million
-22,797 Reduced 82.16%
4,950 $210,000
Q2 2021

Aug 06, 2021
SELL
$31.29 - $56.64 $433,522 - $784,747
-13,855 Reduced 33.3%
27,747 $1.28 Million
Q1 2021

May 14, 2021
BUY
$39.71 - $90.58 $1.35 Million - $3.07 Million
33,945 Added 443.32%
41,602 $1.69 Million
Q4 2020

Feb 12, 2021
SELL
$27.07 - $84.35 $119,568 - $372,573
-4,417 Reduced 36.58%
7,657 $586,000
Q1 2020

May 11, 2020
BUY
$14.88 - $32.78 $22,007 - $48,481
1,479 Added 13.96%
12,074 $244,000
Q4 2019

Feb 12, 2020
SELL
$19.49 - $32.63 $150,911 - $252,654
-7,743 Reduced 42.22%
10,595 $313,000
Q3 2019

Nov 14, 2019
BUY
$22.49 - $26.81 $217,365 - $259,118
9,665 Added 111.44%
18,338 $412,000
Q2 2019

Aug 20, 2019
BUY
$20.48 - $27.76 $177,623 - $240,762
8,673 New
8,673 $215,000

Others Institutions Holding EDIT

# of Institutions
248
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email